Kim Hye Yeon, Seo Hae Sun, Seo Hee Ae, Doh Tae Yun, Chang Gyu Tae, Lee Jin Yong, Lee Sun Haeng
Department of Korean Pediatrics, Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Republic of Korea.
Department of Clinical Korean Medicine, College of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul, Republic of Korea.
Medicine (Baltimore). 2024 May 3;103(18):e37970. doi: 10.1097/MD.0000000000037970.
Deer antlers have been used as strong tonifying medicine in Asian countries, especially for the growth and development of children in pediatrics of Korean medicine. The safety of deer antler in adults cannot be applied directly to children because of their physiological characteristics. To accumulate reliable data on the safety of deer antler in pediatric populations, well-designed clinical studies are required.
This research is a 12-week, randomized, double-blind, placebo-controlled clinical trial evaluating the safety of deer antler extract (DAE) in children. The DAE group received an intervention containing 1586 mg of DAE, whereas the control group received a placebo for 12 weeks. The safety was assessed by monitoring adverse drug reactions (ADRs) and laboratory test results.
One hundred participants were included in the safety analysis. Three and 2 participants in the DAE and control groups, respectively, reported ADRs. There was no significant difference in incidence between the 2 groups. ADRs are categorized into gastrointestinal and skin-related symptoms. No serious ADR was observed throughout the study. The laboratory test results were within or outside the normal range at clinically insignificant levels.
The research discovered that the DAE is safe in terms of ADRs and laboratory parameters under the conditions studied. Further studies are required to accumulate safety data about DAE dosage adjustment and potential interactions with other medicines.
鹿茸在亚洲国家一直被用作强效滋补药物,尤其在韩医学儿科学中用于儿童的生长发育。由于儿童的生理特征,鹿茸在成人中的安全性不能直接应用于儿童。为了积累关于鹿茸在儿科人群中安全性的可靠数据,需要设计良好的临床研究。
本研究是一项为期12周的随机、双盲、安慰剂对照临床试验,评估鹿茸提取物(DAE)在儿童中的安全性。DAE组接受含有1586毫克DAE的干预,而对照组接受安慰剂,为期12周。通过监测药物不良反应(ADR)和实验室检测结果来评估安全性。
100名参与者纳入安全性分析。DAE组和对照组分别有3名和2名参与者报告了ADR。两组之间的发生率无显著差异。ADR分为胃肠道和皮肤相关症状。在整个研究过程中未观察到严重的ADR。实验室检测结果在临床无显著意义的水平上处于正常范围之内或之外。
该研究发现,在所研究的条件下,就ADR和实验室参数而言,DAE是安全的。需要进一步研究以积累关于DAE剂量调整以及与其他药物潜在相互作用的安全性数据。